Is remyelination a reasonable target in PMS?

Abstract

The development of immunotherapies has led to major therapeutic progress in MS, with a robust impact on relapse rate. Concerning their influence on disability accrual, several long-term observational studies have suggested a reduced risk of decline in neurologic function in patients with relapsing-remitting MS. In the progressive forms of the disease, few trials with immunosuppressants have shown some relatively minor effect on progression of handicap. Irreversible neuronal/axonal damage and loss accounts for handicap progression, and takes place early in disease evolution, i.e.